Mallinckrodt to Present at the 38th Annual J.P. Morgan Healthcare Conference
STAINES-UPON-THAMES, United Kingdom, Dec. 23, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that Mark Trudeau, President and Chief Executive Officer, and other members of management will represent the company at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis on Union Square, 335 Powell St., San Francisco. Mallinckrodt is scheduled to present on Monday, Jan. 13, 2020 from 9:00 a.m. to 9:55 a.m. Pacific Time.
Individuals who cannot attend the meeting in person can find webcast information at: http://www.mallinckrodt.com/investors. A replay will also be available following the meeting.
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2019 Mallinckrodt. 12/19
View original content to download multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-300977714.html
SOURCE Mallinckrodt plc